Skip to main content
. 2015 Mar 9;11(5):1277–1292. doi: 10.1080/21645515.2015.1016675

Figure 2.

Figure 2.

The binding sites of representative neutralizing antibodies on the HEV VLP surface. (A) The pORF2 monomer is divided into 3 sections named the S domain (aa 118–313), the P1 domain (aa 314–453) or P domain (aa 320–455) and the P2 domain (aa 454–606) or P domain (aa 456–606), which are shown in color blue, purple, and yellow, respectively. The P2 or P domain is dimeric and harbors all of the identified neutralizing epitopes. The neutralizing epitopes determined by different methods against several neutralizing antibodies are shown in different colors. Such as E479, D481, T484, Y485, S487, Y532 and S533 for FAB244;17 S487, S488, T489, P491, N562 and T564 for MAB1323;15 D496, G591 and P592 for MAB272;15 E479, Y485, I529 and K534 for 8H3; E479, S497, R512, K534, H577 and R578 for 8C11. These antibodies are useful serological markers for evaluating the clinical efficacy of the vaccine. (B) Key neutralizing epitopes on P (P2) domain of pORF2. The S domain, M (P1) domain and P (P2) domain are colored in blue, purple, and yellow, respectively.